Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL20877458

N[C@H]1C[C@H](C(=O)Nc2ncc(C3CCOCC3)s2)C1.O=C(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CCNE1 P24864 6/20 0.41
▸ CDK2 P24941 6/20 0.41
▸ CDK5 Q00535 5/20 0.41
▸ CDK5R1 Q15078 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ UCHL1 P09936 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ CCNE2 O96020 1/20 0.37
▸ CDK9 P50750 1/20 0.36
▸ CNR2 P34972 2/20 0.36
▸ OGA O60502 2/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ HDAC1 Q13547 2/20 0.34
▸ HDAC2 Q92769 2/20 0.34
▸ MKNK1 Q9BUB5 1/20 0.34
▸ HDAC3 O15379 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL20877459 1.00 CCNE1 (0.41) CCNE1CDK2CDK5CDK5R1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL20877543 0.89 CCNE1 (0.50) CCNE1CDK2CDK5CDK5R1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL20877541 0.89 CCNE1 (0.50) CCNE1CDK2CDK5CDK5R1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL29380781 0.80 CCNE1 (0.50) CCNE1CDK2CDK5CDK5R1SMN1; SMN2
SCHEMBL22523005 0.80 CCNE1 (0.54) CCNE1CDK2CDK5CDK5R1SMN1; SMN2
SCHEMBL22522971 0.79 SMN1; SMN2 (0.45) CCNE1CDK2CDK5CDK5R1SMN1; SMN2
SCHEMBL20883081 0.79 SMN1; SMN2 (0.59) CCNE1CDK2CDK5CDK5R1SMN1; SMN2
SCHEMBL20877325 0.76 UCHL1 (0.45) CCNE1CDK2CDK5CDK5R1SMN1; SMN2
SCHEMBL20877327 0.76 UCHL1 (0.45) CCNE1CDK2CDK5CDK5R1SMN1; SMN2
SCHEMBL22522925 0.74 GAA (0.40) CCNE1CDK2CDK5CDK5R1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3692028-B1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS INC (US) 2023-04-26 — — EP disclosed
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2022-06-16 — — US disclosed
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 FORMA THERAPEUTICS, INC. (US) 2022-02-15 — — US disclosed
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2020-10-08 — — US disclosed
EP-3692028-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 Forma Therapeutics, Inc. (US) 2020-08-12 — — EP disclosed
WO-2019071073-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. (US) 2019-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 USP30, UCHL1, UCHL3 CCNE1 3461/4885CDK2 1919/4885CDK5 262/4885
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 USP30, UCHL1, UCHL3 CCNE1 2017/4885CDK2 1051/4885CDK5 300/4885
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 USP30, UCHL1, UCHL3 CCNE1 3461/4885CDK2 1919/4885CDK5 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback